Atyr Pharma Inc (ATYR) financials
Atyr Pharma revenue and earnings by year
Atyr Pharma's revenue was $190,000 in the fiscal year to December 31, 2025, down 19.1% from the year before. Net income was -$74.1 million, -39009.5% of revenue. Since the fiscal year to December 31, 2019, revenue has shrunk 12.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 10 | 10 | 0 |
| Revenue growth | -19.1% | -33.4% | -96.6% | -0.7% | 2377.5% | — |
| Operating income | -78 | -68 | -55 | -46 | -16 | -23 |
| Operating margin | -40856.3% | -28899.6% | -15557.8% | -446.8% | -152.2% | -5445.0% |
| Net income | -74 | -64 | -50 | -45 | -16 | -24 |
| Net margin | -39009.5% | -27243.8% | -14274.5% | -436.5% | -155.2% | -5593.1% |
| Diluted EPS | -$32.00 | -$34.40 | -$37.60 | -$64.00 | -$63.80 | -$292.00 |
| Free cash flow | -62 | -69 | -37 | -43 | -15 | -20 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ATYR in Markets.
See also: ATYR returns
No forecast, no recommendation. This page describes Atyr Pharma Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.